Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus TP in advanced cervical squamous cell carcinoma
CTR20150790Phase 3Active
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nimotuzumab in cervical squamous cell carcinoma (CSCC), sponsored by Biotech Pharmaceutical Co., Ltd.. Started Jan 2016; status: active.
02
Drugs
nimotuzumab
03
Conditions
cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on CTR20150790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150790.